NASDAQ:NRSN • IL0011809592
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEUROSENSE THERAPEUTICS LTD (NRSN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-22 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-24 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-15 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-07-10 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-12 | D. Boral Capital | Initiate | Buy |
| 2024-12-16 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-07-17 | Alliance Global Partners | Initiate | Buy |
| 2022-01-07 | Maxim Group | Initiate | Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 583.88% | N/A 48.53% | N/A 2,073.46% | N/A 227.79% | N/A 74.76% | N/A 19.70% | N/A 4.60% | |||||||
| EBITDA YoY % growth | -1.24M | -2.89M -133.06% | -5.59M -93.43% | -13.46M -140.79% | -12.028M 10.64% | -9.88M 17.86% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -1.24M | -2.89M -133.06% | -5.59M -93.43% | -13.55M -142.40% | -12.049M 11.08% | -9.902M 17.82% | N/A -13.43% | N/A -5.62% | N/A 2.90% | N/A 13.63% | N/A 1,734.12% | N/A 284.46% | N/A 80.15% | N/A 20.52% | N/A 4.64% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | -0.54 37.72% | N/A 27.28% | N/A 28.57% | N/A 18.18% | N/A -11.11% | N/A 1,320.00% | N/A 102.95% | N/A 64.46% | N/A 20.04% | N/A 4.26% |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.06 49.00% | -0.05 23.50% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -2.236M -6.14% | -1.948M 80.33% |
All data in USD
9 analysts have analysed NRSN and the average price target is 10.37 USD. This implies a price increase of 1133.94% is expected in the next year compared to the current price of 0.8404.
NEUROSENSE THERAPEUTICS LTD (NRSN) will report earnings on 2026-03-25, before the market open.
The consensus EPS estimate for the next earnings of NEUROSENSE THERAPEUTICS LTD (NRSN) is -0.06 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering NEUROSENSE THERAPEUTICS LTD (NRSN) is 9.